A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC).

Jameel Muzaffar(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Kedar Kirtane(Moffitt Cancer Center), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Janaki Parameswaran(Moffitt Cancer Center), Robbert J.C. Slebos(University of Iowa), Jeffery S. Russell(University of Utah), Janis V. de la Iglesia
Journal of Clinical Oncology
May 20, 2019
Cited by 0


Related Papers